Studies have documented both increased and decreased hepatic expression of the angiogenic genes, such as VEGFA and their cognate receptors in patients with NAFLD when compared to control tissues [5,18]. The gene discussed is VEGFA; the disease is metabolic dysfunction-associated steatotic liver disease.